Mike DuVall, PhD, is a self-employed Angel investor with a passion for the convergence of business and science, motivated by the potential to create positive patient impacts. Currently, he is actively involved in start-up investments to foster growth within the healthcare and technology adjacent sectors in the Pacific Northwest. Simultaneously, he serves as a drug discovery scientist at Edgewise Therapeutics, where he focuses on early stage target identification, evaluating therapeutic landscapes, and developing assets in the areas of neuromuscular and cardiovascular research.